Publications by authors named "Christina Landis"
Introduction: Vibegron is a selective β-adrenergic receptor agonist that was approved by the US Food and Drug Administration in December 2020 for the treatment of overactive bladder in adults. This retrospective study assessed US pharmacy claims data to evaluate the real-world adherence and persistence of vibegron compared with mirabegron and with anticholinergics.
Materials And Methods: This analysis used the Optum Research Database to identify adults with ≥1 pharmacy claim for vibegron, mirabegron, or an anticholinergic from April 1, 2021, to August 31, 2022.
Introduction: Vibegron is a β-adrenergic receptor agonist approved for overactive bladder (OAB). This analysis assessed real-world adherence and persistence with vibegron in patients with OAB, along with demographics and clinical characteristics associated with adherence and persistence.
Methods: This retrospective study used the Optum Research Database to identify patients treated with vibegron from April 2021 to August 2022 (identification period).
Article Synopsis
- Muscular dystrophies (MDs) are a diverse group of genetic disorders that lead to progressive muscle weakness and disabilities, with Duchenne MD (DMD) and Becker MD being two of the most common forms.
- The study aimed to create and validate algorithms to identify DMD patients specifically, including their nonambulatory and ventilation-dependent statuses, using administrative claims data linked with electronic health records (EHRs).
- A retrospective cohort of 1,300 male patients diagnosed with Duchenne/Becker MD was analyzed to validate the algorithms, with their performance assessed through positive predictive value and the comparison of algorithm outputs against documented clinical EHR information.
Background: Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by relapsing and remitting inflammation that leads to progressive bowel damage. Despite advances in medical treatment for CD, many patients require surgical intervention. Most studies of surgery rates are from patients treated with anti-tumor necrosis factor alpha (anti-TNFα) treatments, with comparatively little data on the surgery rates of patients treated with vedolizumab and ustekinumab.
View Article and Find Full Text PDF